JenaValve today announced new results from an expanded cohort receiving its Trilogy transcatheter heart valve (THV) system.

JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV) System, presented results from an expanded cohort of 500 patients in the ALIGN-AR Pivotal Trial ...

Findings from the first 500 patients treated with the Trilogy system met noninferiority for both safety and efficacy.

She joined the company Advanced Bionics from JenaValve Technology, a global and innovative transcatheter heart valve company, where she became CEO in mid-2015.

JenaValve Technology, Inc. IRVINE, Calif. and CHICAGO, March 31, 2025 (GLOBE NEWSWIRE) -- JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV ...